SDCBP2

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, SDCBP2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SDCBP2 data layer compared with 17 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher SDCBP2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SDCBP2 expression acts as an unfavorable survival marker.

READ, STAD, and UCEC are the cancer types where SDCBP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
READDFSMedianAll0.0840.845<.00112view →
STADOSMedianIV0.0010.544<.00112view →
UCECOSMedianIV0.2310.592.0366view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SDCBP2–READ (DFS)

Kaplan–Meier survival curve for SDCBP2 mutant vs wild-type samples in READ.

Open the READ breakdown →

Exploration